Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer - press release

".... Accordingly, Roche and Genentech have indicated that they plan to further analyze the data, including subset analyses in the coming months. Following these analyses, they expect to make a portfolio decision regarding whether, or to what extent, they will continue development of GDC-0449 in advanced ovarian cancer.

“While we await the final analysis of the data from this advanced ovarian cancer study, we remain optimistic about the continued evaluation of GDC-0449 in tumors such as basal cell carcinoma”

No obvious new safety signals were observed in patients treated with GDC-0449. It is expected that data from this Phase II study will be submitted for presentation at an upcoming medical meeting....cont'd

Review: Targeting the Hedgehog pathway in cancer - abstract

"The orally available compound, GDC-0449, is the farthest along in clinical development. Initial clinical trials in basal cell carcinoma and treatment of select patients with medulloblastoma have shown good efficacy and safety."

PharmaLive: Curis / GDC-0449 [phase 11 trial results to follow

Note:  excerpt - Avastin + chemo

"Genentech and Roche are also conducting a randomized double-blind placebo-controlled Phase II trial in advanced ovarian cancer in a maintenance setting, which is evaluating the ability of GDC-0449 to slow the time to recurrence of cancer in patients whose disease is in complete remission, by impeding the residual cancer cells' ability to grow. Roche has indicated that results from this study are expected during the second half of 2010."

Curis Reports First Quarter 2010 Financial news

"Genentech also reported in April that:

-- It expects results from ongoing Phase II clinical trials of GDC-0449 in first-line metastatic colorectal in mid-2010 and in advanced ovarian cancer during the second half of 2010."

Curis to Present at the 17th Annual Future Leaders in the Biotech Industry Conference - Hedgehog Pathway inhibitor GDC-0449 (financial news)

"Dan Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor. GDC-0449 is currently being developed in three Phase II clinical trials by Curis' collaborator Genentech, including in a pivotal Phase II trial in advanced basal cell carcinoma and Phase II trials in metastatic colorectal cancer and advanced ovarian cancer. Mr. Passeri will also discuss CUDC-101, Debio 0932 and Curis' other targeted cancer programs, in addition to other corporate activities.

There will be a corresponding webcast of the presentation, which can be accessed by visiting:

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=CRIS&item_id=2957649

The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com."